

Abstract 5381: Elevated PD-L1 and HER2 expression on aneuploid carcinoma cells in malignant ascites accelerate tumor cell immune evasion in gastrointestinal cancer patients

Yang Chen, Changsong Qi, JiaJia Yuan, Dan Liu, Zhi Peng, Xiaotian Zhang, Jian Li, Pin Peter Lin, Yilin Li, and Lin Shen

DOI: 10.1158/1538-7445.AM2020-5381 Published August 2020 [Check for updates](#)

Article

Info & Metrics

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

Abstract

Background Peritoneal dissemination (PD) is a type of metastasis frequently found in gastrointestinal (GI) cancer patients, resulting in the production of massive malignant ascites which associate with poor prognosis. However, the question of how the expression of tumor biomarkers on cancer cells in malignant ascites correlates with PD is yet to be answered. This study aims to investigate the clinical significance of PD-L1 and HER2 expression on malignant ascites disseminated tumor cells (maDTCs) in GI carcinoma patients.

Patients and Methods Paired blood and malignant ascites specimens were respectively collected from 24 of metastatic GI subjects, including 15 gastric, 2 pancreatic, 1 esophageal, and 6 colorectal cancer patients. Non-hematologic CTCs and maDTCs were enriched by subtraction enrichment (SE), followed by immunostaining-FISH (iFISH) to co-examine PD-L1 and HER2 expression on aneuploid maDTCs and CTCs. In addition, CD4⁺, CD8⁺, Treg and naive T cells in the same cohort of samples were quantified by flow cytometry.

Results *In situ* karyotypic and phenotypic characterization performed by iFISH showed that the average number of maDTCs in the 24 patients was 32755/ml ascites, which was significantly higher than the average number of CTCs detected (3.5/ml blood) ($P < 0.0001$). The number of maDTCs and CTCs exhibited no correlation between each other (Pearson's product-moment correlation coefficient, $R = -0.03$, $P = 0.89$). Further examination indicated that PD-L1 was expressed on 50% of maDTCs compared to only 11% for CTCs ($P = 0.0002$). No correlation of PD-L1 expression between maDTCs and CTCs was observed (Pearson's product-moment correlation coefficient, $R = 0.25$, $P = 0.24$). Co-expression of PD-L1 and HER2 on CTCs and maDTCs was respectively examined in the recruited 15 gastric cancer (GA) patients. All 15 patients were histopathological HER2 negative (hHER2⁻). One subject (1/15=6.7%) showed 1 double HER2⁺/PD-L1⁺ CTC (1/63 CTCs in 15 GA patients=1.6%). In comparison, 6 patients (6/15=40%) had a total of 290377 HER2⁺/PD-L1⁺ maDTCs detected (290377/1306783 overall maDTCs=22%). In addition, flow cytometry analyses revealed that 5% of lymphocytes in malignant ascites were immunosuppression relevant regulatory T cells (Tregs), compared to only 2% of Tregs identified in the paired peripheral blood sample of the same patient.

Conclusions Our study suggested that a higher proportion of Tregs in malignant ascites may contribute towards fostering an immunosuppressive microenvironment. PD-L1⁺/HER2⁺ maDTCs, in such an immunosuppressive microenvironment, might be able to evade immune system attack. Moreover, PD-L1 and HER2 identified on maDTCs could serve as therapy targets with respect to inhibition of peritoneal metastasis, potentially leading to an additional treatment strategy for GI cancer patients with malignant ascites.

Citation Format: Yang Chen, Changsong Qi, JiaJia Yuan, Dan Liu, Zhi Peng, Xiaotian Zhang, Jian Li, Pin Peter Lin, Yilin Li, Lin Shen. Elevated PD-L1 and HER2 expression on aneuploid carcinoma cells in malignant ascites accelerate tumor cell immune evasion in gastrointestinal cancer patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5381.

©2020 American Association for Cancer Research.



August 2020
Volume 80,
Issue 16
Supplement
Table of
Contents

Search this issue

Sign up for alerts

© Permissions

Share

Article Alerts

Tweet

Email Article

Like 0

Citation Tools

Jump to section

Article

Info & Metrics

Advertisement

Investigating colocalized inhibition of TGF-β and PD-L1 with bintrafusp alfa

Bintrafusp alfa is under clinical investigation and has been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after by any health authority worldwide.

INTR@PID CLINICAL TRIALS

ACTIVE TRIALS:
BTC, NSCLC, CERVICAL AND UROTHELIAL CANCERS

[CLICK TO LEARN MORE](#)

Being developed in a strategic global alliance between Merck KGaA, Darmstadt, Germany and GSK, EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the United States and Canada. © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. LQ75407020/0102 | 028942/INT@PID/2020023 | 02-08-094-4017-00006 | June 2020

Related Articles

No related articles found.

Google Scholar

Cited By...

More in this TOC Section

Jump to section

Article

Info & Metrics